Bayer, National Heart Center Singapore to develop explorative cardiovascular center
By Anh Nguyen December 22, 2020 | 04:43 pm GMT+7
Bayer and National Heart Center Singapore (NHCS) announced they had inked a five-year agreement to develop a “Center of Excellence for Explorative Cardiovascular Studies.”
The center aims to boost patient-centricity in research and development (R&D) and improve treatment outcomes in cardiovascular disease (CVD) management.
Combining NHCS’s vast experience in managing Asian CVD patients and clinical research with Bayer’s expertise in pharmaceutical R&D, the center will generate and integrate high quality patient data into early clinical research that would allow better understanding of the underlying biology of CVDs. Results could potentially lead to future targeted therapies to address unmet medical needs in defined patient populations. Bayer will contribute S$5.4 million ($4 million) towards the setup of the center.
E-Mail
Leveraging on Asian patient data, the 5-year collaboration aims to boost patientcentricity in R&D, leading to improved treatment outcomes in cardiovascular disease (CVD) management.
The Center will generate and integrate high quality patient data into early clinical research to inform future targeted therapies for CVDs.
Bayer will contribute S$5.4million (approx. EUR 3.4 million) towards this
collaboration.
Singapore, December 17, 2020 - Bayer and National Heart Centre Singapore (NHCS) today announced that they have entered into a 5-year collaboration agreement to set up Center of Excellence for Explorative Cardiovascular Studies (hereinafter Center ) with the aim of boosting patient-centricity in research and development (R&D) and improving treatment outcomes in cardiovascular disease (CVD) management. Combining NHCS vast